Immunoadjuvant activity of a liposomal IL-6 formulation

Area of Science:

• Immunology
• Vaccinology
• Biotechnology

Background:

• Interleukin 6 (IL-6) plays a role in adjuvant activity, as evidenced by elevated serum IL-6 levels induced by various adjuvants.
• Liposomes are effective delivery systems for antigens and bioactive molecules.
• The development of novel adjuvants is crucial for enhancing vaccine efficacy, particularly for antigens with low immunogenicity.

Purpose of the Study:

• To evaluate the adjuvant effect of interleukin 6 (IL-6) encapsulated in liposomes.
• To assess the impact of IL-6-containing liposomes on the humoral immune response to a model antigen (65 kDa heat shock protein).
• To compare the adjuvanticity of liposomal IL-6 formulations with established adjuvants like Ribi and dimethyldioctadecylammoniumbromide (DDA).

Main Methods:

• Balb/c mice were immunized with a model antigen (65 kDa heat shock protein) alone, incorporated into liposomes, or with IL-6 entrapped in liposomes.
• Humoral immune responses, specifically secondary antibody titers, were measured.
• The biological activity of liposomal IL-6 was confirmed using the IL-6-dependent B9 cell line.
• Adjuvant formulations were compared to Ribi and DDA.

Main Results:

• IL-6 retained its biological activity when entrapped in liposomes.
• Liposomal antigen formulation induced measurable secondary antibody titers, even at antigen doses where Ribi and DDA showed minimal or no response.
• Co-injection of liposomes containing IL-6 with liposomal antigen significantly enhanced adjuvant activity.
• All tested adjuvants induced high serum IL-6 levels, supporting IL-6's role in adjuvant activity.

Conclusions:

• Liposomes containing IL-6 demonstrate significant potential as vaccine adjuvants.
• This formulation is particularly promising for enhancing the immunogenicity of weak or non-immunogenic antigens.
• The combination of liposomal antigen and co-administered liposomal IL-6 offers a potent strategy for vaccine development.